Recently, the third generation FLT3i gilteritinib has been approved for patients with r/r AML, demonstrating a clinically relevant survival advantage in those AML patients that harbor either FLT3-ITD or FLT3-TKD mutations [15]. The gene discussed is FLT3; the disease is acute myeloid leukemia.